These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11092715)

  • 1. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration.
    Johnson JL; Okwera A; Nsubuga P; Nakibali JG; Whalen CC; Hom D; Cave MD; Yang ZH; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 2000 Nov; 4(11):1032-40. PubMed ID: 11092715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.
    Johnson JL; Okwera A; Vjecha MJ; Byekwaso F; Nakibali J; Nyole S; Milberg J; Aisu T; Whalen CC; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):446-53. PubMed ID: 9441100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala.
    Okwera A; Johnson JL; Luzze H; Nsubuga P; Kayanja H; Cohn DL; Nunn P; Ellner JJ; Whalen CC; Mugerwa RD
    Int J Tuberc Lung Dis; 2006 Jan; 10(1):39-44. PubMed ID: 16466035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
    Okwera A; Whalen C; Byekwaso F; Vjecha M; Johnson J; Huebner R; Mugerwa R; Ellner J
    Lancet; 1994 Nov; 344(8933):1323-8. PubMed ID: 7526098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy.
    Schwander SK; Dietrich M; Mugyenyi P; Kityo C; Okwera A; Johnson J; Nsubuga P; Ruesch-Gerdes S; Whalen C
    East Afr Med J; 1997 Sep; 74(9):543-8. PubMed ID: 9487427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis.
    Joloba ML; Johnson JL; Namale A; Morrissey A; Assegghai AE; Mugerwa RD; Ellner JJ; Eisenach KD
    Int J Tuberc Lung Dis; 2000 Jun; 4(6):528-36. PubMed ID: 10864183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration.
    Johnson JL; Vjecha MJ; Okwera A; Hatanga E; Byekwaso F; Wolski K; Aisu T; Whalen CC; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1998 May; 2(5):397-404. PubMed ID: 9613636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis.
    Schwander S; Rüsch-Gerdes S; Mateega A; Lutalo T; Tugume S; Kityo C; Rubaramira R; Mugyenyi P; Okwera A; Mugerwa R
    Tuber Lung Dis; 1995 Jun; 76(3):210-8. PubMed ID: 7548903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
    Johnson JL; Okwera A; Hom DL; Mayanja H; Mutuluuza Kityo C; Nsubuga P; Nakibali JG; Loughlin AM; Yun H; Mugyenyi PN; Vernon A; Mugerwa RD; Ellner JJ; Whalen CC;
    AIDS; 2001 Nov; 15(16):2137-47. PubMed ID: 11684933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
    Kassim S; Sassan-Morokro M; Ackah A; Abouya LY; Digbeu H; Yesso G; Coulibaly IM; Coulibaly D; Whitaker PJ; Doorly R
    AIDS; 1995 Oct; 9(10):1185-91. PubMed ID: 8519456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months.
    Perriëns JH; St Louis ME; Mukadi YB; Brown C; Prignot J; Pouthier F; Portaels F; Willame JC; Mandala JK; Kaboto M
    N Engl J Med; 1995 Mar; 332(12):779-84. PubMed ID: 7862181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection.
    Jones BE; Otaya M; Antoniskis D; Sian S; Wang F; Mercado A; Davidson PT; Barnes PF
    Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1499-502. PubMed ID: 7952606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
    Whalen CC; Johnson JL; Okwera A; Hom DL; Huebner R; Mugyenyi P; Mugerwa RD; Ellner JJ
    N Engl J Med; 1997 Sep; 337(12):801-8. PubMed ID: 9295239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.